Poland's Diagnostyka debuts 19.5% above IPO price in Warsaw (updated)
07/02/2025 08:26
(Adds details on IPO and context from paragraph 3)
GDANSK, Feb 7 (Reuters) - Shares of Polish medical
diagnostics company Diagnostyka DIAP.WA soared 19.5% at their
stock market debut on Friday, after it completed Warsaw's first
initial public offering (IPO) this year.
The company had priced its IPO at 105 zlotys per share,
giving it a valuation of 3.54 billion zlotys ($877.7 million).
Friday's debut price of 125.5 zlotys drove that up to 4.24
billion zlotys.
Diagnostyka's shareholder LX Beta, backed by private equity
fund Mid Europa Partners, offered 16.1 million shares in the
IPO, bringing the value of the offering to 1.70 billion zlotys.
The offering followed convenience store chain Zabka's
ZAB.WA 6.45 billion zloty share sale in October, the biggest
IPO in Poland since Allegro's ALEP.WA in 2020.
Diagnostyka, which performs blood, microbiological and
genetic tests as well as diagnostic imaging, did not receive any
proceeds from the IPO.
Founded in 1998, the company describes itself as a market
leader in Poland's medical diagnostics industry, with more than
1,100 blood collection points, 156 laboratories, and 19 imaging
facilities.
($1 = 4.0331 zlotys)
(Reporting by Marta Maciag and Julia Kotowska; Editing by Milla
Nissi)
((Marta.Maciag@thomsonreuters.com; +48 58 746 91 96))